Mergers & Acquisitions ·
RedHill Biopharma sells 70% stake in Talicia to Apotex for up to $53M and licenses Rebyota from Ferring for $12M
RDHLRedHill Biopharma Ltd.
RedHill Biopharma completed the sale of its 70% stake in Talicia Holdings to Apotex on August 27, 2026, receiving an $18.0 million upfront payment and up to $35.0 million in potential sales milestones. Concurrently, it entered a License and Commercial Supply Agreement with Ferring Pharmaceuticals for exclusive global rights to Rebyota and U.S. rights to Clenpiq, paying $12 million upfront plus royalties and contingent payments. These transactions resulted in stockholders' equity exceeding $5 million as of September 30, 2026. The company operates in the biopharmaceutical industry.